Malcolm Brenner, MD, PhD

  • 33943 Citations
  • 95 h-Index
1979 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Personal profile

Dr. Brenner completed his postdoctoral training in 1981 and joined the Clinical Research Centre of Northwick Park Hospital in London, England as a MRC Clinical Scientist and Honorary Senior Registrar. He also began lecturing in Haematology at the Royal Free Hospital and Hospital for Sick Children, also in London.

Dr. Brenner joined the faculty at the University of Tennessee in Memphis as a Professor in the Departments of Pediatrics and Medicine in 1990. He also became the Director of the Bone Marrow Transplant Division of the St. Jude Children's Research Hospital that same year. He later directed the Cell and Gene Therapy Program at St. Jude's from 1994 until 1997, when he assumed his current positions at the Baylor College of Medicine.

Research interests

Dr. Brenner's research focuses on gene transfer to stem cells and to effector cells of the immune system. His research group was one of the first to use gene transfer in human subjects, establishing the feasibility of tracking human stem cells and their progeny in subjects with cancer. Dr. Brenner also develops tumor vaccines for pediatric and hematological malignancies, using genetic modification with retroviral and adenoviral vectors.

Education/Academic qualification

PhD, Cambridge University

Free-text keywords

  • Cell therapy
  • Gene therapy
  • Stem cells
  • Vectors

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors

Porter, C. E., Rosewell Shaw, A., Jung, Y., Yip, T., Castro, P. D., Sandulache, V. C., Sikora, A., Gottschalk, S., Ittman, M. M., Brenner, M. & Suzuki, M., May 6 2020, In : Molecular Therapy. 28, 5, p. 1251-1262 12 p.

Research output: Contribution to journalArticle

  • 5 Scopus citations

    The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma

    Lulla, P. D., Tzannou, I., Vasileiou, S., Carrum, G., Ramos, C. A., Kamble, R., Wang, T., Wu, M., Bilgi, M., Gee, A. P., Mukhi, S., Chung, B., Wang, L., Watanabe, A., Kuvalekar, M., Jeong, M., Li, Y., Ketkar, S., French-Kim, M., Grilley, B. & 4 others, Brenner, M., Heslop, H., Vera, J. F. & Leen, A. M., Jul 29 2020, In : Science translational medicine. 12, 554

    Research output: Contribution to journalArticle

  • Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma

    Hegde, M., Joseph, S. K., Pashankar, F., DeRenzo, C., Sanber, K., Navai, S., Byrd, T. T., Hicks, J., Xu, M. L., Gerken, C., Kalra, M., Robertson, C., Zhang, H., Shree, A., Mehta, B., Dakhova, O., Salsman, V. S., Grilley, B., Gee, A., Dotti, G. & 5 others, Heslop, H., Brenner, M. K., Wels, W. S., Gottschalk, S. & Ahmed, N., Jul 15 2020, In : Nature Communications. 11, 1, 3549.

    Research output: Contribution to journalArticle

  • Adoptive Cell Therapy: ACT-Up or ACT-Out?

    Brenner, M. K., Apr 10 2019, In : Molecular Therapy. 27, 4, p. 693-694 2 p.

    Research output: Contribution to journalEditorial

    Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia

    Lulla, P. D., Mamonkin, M. & Brenner, M. K., May 1 2019, In : Cancer Journal (United States). 25, 3, p. 199-207 9 p.

    Research output: Contribution to journalReview article